4.3 Article

Slowing progression of chronic kidney disease

Journal

KIDNEY INTERNATIONAL SUPPLEMENTS
Volume 3, Issue 4, Pages 372-376

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1038/kisup.2013.80

Keywords

blood pressure target; chronic kidney disease; endothelin; progression; renin-angiotensin-aldosterone

Funding

  1. National Institutes of Health/National Institute of Digestive Diseases, Diabetes, and Kidney Disease (NIDDK) [K23DK087919]
  2. CytoPherx
  3. American Society of Nephrology
  4. US Department of Veterans Affairs
  5. Turkish Society of Hypertension and Renal Diseases

Ask authors/readers for more resources

Early identification of chronic kidney disease (CKD) provides an opportunity to implement therapies to improve kidney function and slow progression. The goal of this article is to review established and developing clinical therapies directed at slowing progression. The importance of controlling blood pressure will be discussed along with the target blood pressure that should be achieved in CKD patients. Therapy directed at inhibiting the renin-angiotensin-aldosterone system remains the mainstay of treatment with single-agent inhibition of this system being as good as dual blockade with fewer adverse effects. Other therapies that may be used include correction of metabolic acidosis, dietary protein restriction, and new models for delivering care to patients with CKD. Emerging therapies targeting endothelin, uric acid, kidney fibrosis, and oxidant stress hold promise for the future.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available